Evidence map›Paper›PMID 41031396›Full record

ArticleCirculation research2025

IGFBP2 Mediates Human iPSC-Cardiomyocyte Proliferation in a Cellular Contact-Dependent Manner.

Soah Lee, Paul Heinrich, Daniel Lee, Yongwon Kang, Harley R Robinson, Sean J Humphrey, Jihye Yun, William R Goodyer, Jan W Buikema, David T Paik and 10 more

Abstract read
In one paragraph

Article in Circulation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Soah Lee *Stanford Cardiovascular Institute (S.L., P.H., D.L., W.R.G., D.T.P., F.X.G., N.B., S.M.W.), Stanford University School of Medicine, CA.
Paul Heinrich *Stanford Cardiovascular Institute (S.L., P.H., D.L., W.R.G., D.T.P., F.X.G., N.B., S.M.W.), Stanford University School of Medicine, CA.ORCID 0000-0003-4899-8343
Daniel LeeStanford Cardiovascular Institute (S.L., P.H., D.L., W.R.G., D.T.P., F.X.G., N.B., S.M.W.), Stanford University School of Medicine, CA.
Yongwon KangDepartment of Biopharmaceutical Convergence (S.L., Y.K., J.Y., B.K., J.L.), Sungkyunkwan University, Suwon, South Korea.ORCID 0009-0000-1347-7439
Harley R RobinsonCardiac Bioengineering Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia (H.R.R., J.E.H.).ORCID 0000-0002-9374-5532
Sean J HumphreyMurdoch Children's Research Institute, Royal Children's Hospital, Melbourne, VIC, Australia (S.J.H.).ORCID 0000-0002-2666-9744
Jihye YunDepartment of Biopharmaceutical Convergence (S.L., Y.K., J.Y., B.K., J.L.), Sungkyunkwan University, Suwon, South Korea.ORCID 0009-0004-4270-3107
William R GoodyerStanford Cardiovascular Institute (S.L., P.H., D.L., W.R.G., D.T.P., F.X.G., N.B., S.M.W.), Stanford University School of Medicine, CA.ORCID 0000-0002-3252-1180
Jan W BuikemaAmsterdam Cardiovascular Sciences, Department of Physiology, VU University and Amsterdam Heart Center and Department of Cardiology, Amsterdam University Medical Center, the Netherlands (J.W.B.).ORCID 0000-0001-9313-0602
David T PaikStanford Cardiovascular Institute (S.L., P.H., D.L., W.R.G., D.T.P., F.X.G., N.B., S.M.W.), Stanford University School of Medicine, CA.ORCID 0000-0002-7830-312X
Francisco X GaldosStanford Cardiovascular Institute (S.L., P.H., D.L., W.R.G., D.T.P., F.X.G., N.B., S.M.W.), Stanford University School of Medicine, CA.ORCID 0000-0002-7985-4521
Boyoung KimDepartment of Biopharmaceutical Convergence (S.L., Y.K., J.Y., B.K., J.L.), Sungkyunkwan University, Suwon, South Korea.ORCID 0009-0000-7250-8565
Nadjet BelbachirStanford Cardiovascular Institute (S.L., P.H., D.L., W.R.G., D.T.P., F.X.G., N.B., S.M.W.), Stanford University School of Medicine, CA.
Sungjin MinDepartment of Biotechnology, Yonsei University, Seoul, South Korea (S.M., S.-W.C.).ORCID 0000-0002-5041-8638
Seung-Woo ChoDepartment of Biotechnology, Yonsei University, Seoul, South Korea (S.M., S.-W.C.).ORCID 0000-0001-8058-332X
Jaecheol LeeDepartment of Biopharmaceutical Convergence (S.L., Y.K., J.Y., B.K., J.L.), Sungkyunkwan University, Suwon, South Korea.ORCID 0000-0002-2070-7463
Alessandra MorettiRegenerative Medicine in Cardiovascular Diseases, First Department of Medicine, Cardiology, Klinikum rechts der Isar (P.H., A.M.), School of Medicine and Health, Technical University of Munich, Germany.ORCID 0000-0001-5782-7832
Joseph C WuDivision of Cardiology, Department of Medicine (J.C.W., S.M.W.), Stanford University School of Medicine, CA.ORCID 0000-0002-6068-8041
James E HudsonCardiac Bioengineering Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia (H.R.R., J.E.H.).ORCID 0000-0003-0832-9356
Sean M WuStanford Cardiovascular Institute (S.L., P.H., D.L., W.R.G., D.T.P., F.X.G., N.B., S.M.W.), Stanford University School of Medicine, CA.ORCID 0000-0002-0000-3821

Funding

From proteins to cells to tissues: A multi-scale assessment of biomechanical regulation by the myosin molecular motorRM1GM131981 · NIGMS · STANFORD UNIVERSITY · PI BERNSTEIN, DANIEL, MACK, DAVID LEE · 2019 to 2023
$10.3M
Reawakening cardiomyocyte proliferation from structural mediated quiescenceR01HL171574 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI James F Martin, Sean M Wu · 2024 to 2026
$1.9M
The Role of Sarcomeric Protein Alignment in Connexin 43 Localization at Gap JunctionF32HL142205 · NHLBI · STANFORD UNIVERSITY · PI LEE, SOAH · 2018 to 2020
$188k
NHLBI NIH HHS F32 HL142205NHLBI NIH HHS R01 HL171574NIGMS NIH HHS RM1 GM131981
6 · The paper itself

Abstract

backgroundInduction of cardiomyocyte proliferation in situ represents a promising strategy for myocardial regeneration following injury. However, cardiomyocytes possess intrinsic inhibitory mechanisms that attenuate pro-proliferative signaling and constrain their expansion. We hypothesized that cell-cell contact is a key suppressor of cardiomyocyte proliferation. We aimed to delineate the underlying molecular pathways to enable sustained proliferation in 3-dimensional contexts.

methodsHuman induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were cultured at varying plating densities to examine the impact of cell-cell contact on cell cycle activity. Phosphoproteomic profiling was performed in sparse versus dense cultures to identify signaling alterations. Conditioned media from sparse cultures were interrogated using a human growth factor array to identify secreted pro-proliferative factors.

resultshiPSC-CM proliferation increased proportionally with plating density until intercellular contacts were established, at which point proliferation was suppressed. Dense cultures exhibited enhanced adherens junction assembly, sarcomeric organization, and contractile function. Increased cell-cell contact in dense conditions attenuated nuclear translocation of β-catenin and reduced TCF/LEF (T cell factor/lymphoid enhancer factor family) transcriptional activity, providing a mechanistic basis for the reduced hiPSC-CM proliferation. Disruption of adherens junctions or sarcomere assembly via siRNA-mediated knockdown of N-cadherin or α-actinin, respectively, resulted in increased cell cycle activation of hiPSC-CMs, but this was not sufficient to drive division of hiPSC-CMs. Additional screening for putative secreted growth factors in the conditioned media from sparsely plated hiPSC-CMs revealed the enrichment of IGFBP2 (insulin-like growth factor-binding protein 2), which was sufficient to drive hiPSC-CM division in the presence of cell-cell contact in 3-dimensional constructs.

conclusionsOur findings demonstrate that cell-cell contact inhibits hiPSC-CM proliferation through adherens junction formation, sarcomeric assembly, and reduced IGFBP2 secretion. Importantly, exogenous supplementation of IGFBP2 can overcome cell contact-mediated inhibition of hiPSC-CM proliferation and facilitate the growth of 3-dimensional cardiac tissue. These insights provide valuable implications for advancing cardiac tissue engineering and regenerative therapies.

Indexed as

Cell CommunicationCell ProliferationInduced Pluripotent Stem CellsInsulin-Like Growth Factor Binding Protein 2Myocytes, CardiacAdherens Junctionsbeta CateninCells, CulturedHumansSignal Transductionbeta CateninCTNNB1 protein, humanIGFBP2 protein, humanInsulin-Like Growth Factor Binding Protein 2actinincadherinscateninsmyocardiumsarcomeres

Identifiers

PMID41031396
PMCPMC12533503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.